Investigational drug · Phase 2
BN104
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for ALL, Adult, AML, Adult, Acute Leukaemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "BN104"
First trial start
2023
Oct 19, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BN104", any sponsor or status.
Conditions studied
As listed on its trial records.
- ALL, Adult
- AML, Adult
- Acute Leukaemia
- KMT2A Rearrangement
- NPM1 Mutation
- NUP98 Gene Rearrangement
- Menin Inhibitors
Largest trials
Live from ClinicalTrials.gov: studies naming "BN104" as an intervention, largest first.
Chen SuningAcademic, hospital or other
NCT06746519 · 135 participants (planned) · Start Dec 25, 2024 · Primary completion Dec 30, 2025
Drug: BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine · For: Acute Myeloid Leukemia
Sites: Suzhou, China
- A Study of BN104 in the Treatment of Acute LeukemiaActive, not recruiting
Institut de Recherches Internationales Servier (I.R.I.S.)Industry
NCT06052813 · 66 participants · Start Oct 19, 2023 · Primary completion Dec 2026
Drug: BN104 monotherapy; BN104 monotherapy and 1 more · For: ALL, Adult; AML, Adult; Acute Leukaemia and 4 more
Sites: Suzhou, China
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT07101497 · 60 participants (planned) · Start Aug 1, 2025 · Primary completion Dec 31, 2027
Drug: BN104 monotherapy · For: Menin Inhibitors; Post Hematopoietic Stem Cell Transplantation; Maintenance Therapy and 4 more
Sites: Suzhou, China
BioNova Pharmaceuticals (Shanghai) LTD.Industry
NCT06724549 · 16 participants · Start Jan 12, 2025 · Primary completion Feb 13, 2025
Drug: BN104 · For: Health Subjects
Sites: Changsha, China
Newest research
PubMed records naming it or its code names, newest first.
- Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting.
Cao G, Zhang H, Sun S, et al. · J Hematol Oncol 2025
- MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting.
Sun J, Yu W, Zhang X · Exp Hematol Oncol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.